Half Year 2025 Chrysos Corporation Ltd Earnings Call Transcript
Key Points
- Chrysos Corp Ltd (ASX:C79) reported a 54% year-on-year increase in total revenue, reaching $29.1 million, driven by the adoption of their PhotonAssay technology.
- EBITDA grew by 150% year-on-year to $5.7 million, with an improved EBITDA margin of 20%, reflecting increased economies of scale.
- The company has a strong cash position of $26.9 million, supported by a $95 million debt facility, with a net available cash of $121.9 million for future growth.
- Chrysos Corp Ltd (ASX:C79) deployed 5 new PhotonAssay units during the half, bringing the total to 34 deployed units, with 22 more contracted units yet to be deployed.
- The company has secured 6 new lease agreements, expanding its customer base and supporting ongoing asset rollout, with significant growth opportunities in international markets.
- Revenue guidance is tracking towards the lower end due to timing delays in the deployment of some earlier contracts.
- EBITDA guidance is tracking below the midpoint, influenced by lower additional assay charges as a percentage of revenue.
- The company faces challenges in accelerating deployment cadence, requiring a broader customer base and deeper pipeline.
- Despite strong growth, Chrysos Corp Ltd (ASX:C79) represents only a small proportion of the global gold assay market, indicating potential market penetration challenges.
- The company is exposed to potential tariffs in the US, although it represents a relatively small market compared to other regions.
Thank you for standing by and welcome to the Chrysos Corporation Limited, H1 FY25 result. All participants are in listen only mode. There will be a presentation followed by a question-and-answer session.
(Operator Instructions)
I would now like to hand the conference over to Mr. Dirk Treasure, CEO. Please go ahead.
Thank you, very much and good morning shareholders. Thank you all for joining us today for our first half FY25 results presentation. As usual, I'm joined by our CFO Brett Coventry. Brent and I will give you an overview of the operational and financial results for the half.
Slide 3, operator.
I'd like to start with a brief summary of Chrysos PhotonAssay technology and our market opportunity.
As investors on the core would know, we operate predominantly in the gold analysis space. Gold analysis is a non-discretionary requirement for all gold miners around the world, and prior to adoption of PhotonAssay, miners are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
